NSE: EMAMILTD | BSE: 531162

Mid-range Performer

Download real time

553.80 -4.05 (-0.73%)

High volume today

NSE 29 Sep, 2025 3:31 PM (IST)

24,173.4

Market Cap

Below industry Median

0.6

Beta 1Year

Very Low volatility

Emami Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for EMAMILTD, BSE:531162 Emami Ltd.

Emami Ltd.

09 Nov 2020

553.80

-0.73%

Axis Alpha: Emami Ltd - (BUY)

Buy: Emami Ltd.

Target

Axis Direct

We recommend a BUY on EMAMI LTD with a Target Price of Rs 413 an upside of 10% from CMP of Rs. 375 and Stop Loss Rs 355

Emami Ltd. has lost -26.32% in the last 1 Year

Emami Ltd.

08 Nov 2020

553.80

-0.73%

Strong results; near-term outlook improving significantly

Buy: Emami Ltd.

Target

Motilal Oswal

Emami (HMN) posted a beat on all fronts in its 2QFY21 results. Importantly, (a) strengthening rural growth (50% of HMN's sales), (b) extremely strong health and hygiene sales, (c) initial good winter demand, and (d) the low winter season sales base of last year augur well for sales and earnings growth over the next few quarters. We remain bullish on the stock, despite two primary concerns. (a) The likely delay in pledge reduction to zero (earlier targeted by Mar'21; currently at ~40% levels) is disappointing. (b) There is no evidence of a structural...

Emami Ltd. is trading at high day volume of 2.6M.

Emami Ltd.

06 Nov 2020

553.80

-0.73%

Q2FY21 Result Update - In a sweet Spot; BUY

Buy: Emami Ltd.

Target

Prabhudas Lilladhar

We are changing FY21/22/23 EPS estimates by 9.3%, 1.1% and -3.6% and increase target price to Rs450 @26xSept21 EPS (Rs419 earlier, valuing at 25xJune22EPS). We believe Emami is in a sweet spot given 1) highest rural salience at 55% of sales 2) early onset of winter and low base for winter...

Emami Ltd. is trading below all available SMAs

Emami Ltd.

06 Nov 2020

553.80

-0.73%

Emami

Accumulate: Emami Ltd.

Recommendation Target

Dolat Capital

Emami's Q2FY21 results came ahead of our estimates. Domestic business jumped 13%, while IB posted 11% revenue growth in Q2. Ex-winter products (88% contri) reported 28% growth was encouraging performance. Kesh King and Pain management range recorded highest ever quarterly sales during the quarter....

Number of FII/FPI investors increased from 337 to 349 in Jun 2025 qtr.

Emami Ltd.

06 Oct 2020

553.80

-0.73%

Emami

Buy: Emami Ltd.

Recommendation Target

Sharekhan

Number of FII/FPI investors increased from 337 to 349 in Jun 2025 qtr.

Emami Ltd.

10 Aug 2020

553.80

-0.73%

Axis Alpha: Emami Ltd (BUY)

Buy: Emami Ltd.

Axis Direct

We recommend a BUY on EMAMI LTD with a Target Price of Rs 325 an upside of 10% from CMP of Rs. 295 and Stop Loss Rs 280.

Emami Ltd. has lost -26.32% in the last 1 Year

Emami Ltd.

07 Aug 2020

553.80

-0.73%

Q1FY21 Result Update - Upgrade to Buy on Improved Visibility

Buy: Emami Ltd.

Prabhudas Lilladhar

600mn savings from cost rationalization measures in FY21. Emami 1Q results were better due to 29% growth in Zandu and Boroplus even as rest of the portfolio was under pressure and declined 44%. Sales are bouncing back with double digit growth in July and outlook is improving led by strong demand for Immunity boosters, revival in Kesh king and Pain Mgt. Emami will also gain from low base in 2H21 and benign input costs. Although we would watch out for success of planned launches, we model 8.8% growth in sales and 11% in EBIDTA and 17.2% in PAT over FY20-23. We value the...

Emami Ltd. is trading at high day volume of 2.6M.

Emami Ltd.

02 Jul 2020

553.80

-0.73%

Emami

Hold: Emami Ltd.

Target

Sharekhan

Emami Limited's (Emami's) Q4FY2020 performance was below our as well as street expectation with revenue and PAT declining by ~17% and ~25%, respectively, during the quarter. Lockdown at the end of the quarter affected pre-season sales of the summer portfolio, resulting in a sharp decline of 19% in domestic revenue (international business decreased by just 4%). Post acquiring required approvals, the company started manufacturing essential products from April 10, 2020, and gradually scaled up its operations to 100% in some of its plants. Trade and supply chain have normalised in few...

Emami Ltd. is trading below all available SMAs

Emami Ltd.

30 Jun 2020

553.80

-0.73%

EARNINGS UPDATE- EMAMI 4QFY20

Sell: Emami Ltd.

Recommendation Target

Chola Wealth Direct

Background: Emami is a FMCG company with niche focus on relatively under penetrated segments such as antiseptic cream, fairness cream, talcum powder, cooling oil, pain balm and pain reliever. Emami's power brands such as Navratna Oil, Boroplus Cream, Zandu & MenthoPlus Balm, Fair & Handsome, Boroplus Powder, Navratna Cool Talc, Fast Relief, SonaChandi & Zandu accounts for 75% of company's sales. Emami sales have grown at a CAGR of 38.5% (FY2010-20)....

Promoters unpledged 2.89% of shares in last quarter. Total pledge stands at 10.50% of promoter holdings

Emami Ltd.

29 Jun 2020, 12:00AM

553.80

-0.73%

Emami

Buy: Emami Ltd.

Dolat Capital

Emami's Q4FY20 results were below our estimate. Domestic business declined 19%, while IB posted 4% revenue de-growth. Weak rural demand coupled with liquidity concerns prior to lockdown; and supply...

Emami Ltd. has lost -26.32% in the last 1 Year

Is Emami Ltd. worth buying?

225 Votes:

Buy 74.67%

Sell 17.33%

Hold 8.0%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf